Please add info@sitcancer.org to your safe senders list.

SITC
Support SITC Membership Meetings About SITC www.sitcancer.org

July 22, 2014

Full Schedule Now Available for CME-Certified
Cancer Immunotherapy Program in La Jolla, CA

Are you or someone you know looking for more information on the ground-breaking cancer treatment options that use the power of the immune system?

Who Should Attend

Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate an understanding of:

  1. Underlying principles of tumor immunology and immunotherapy
  2. Clinical indications for cancer immunotherapy and appropriate selection of patients
  3. Patient management
  4. Therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes

Program Schedule

8:00 am - 8:10 am

Welcome and Overview

Session I: Basic Principles of Tumor Immunology and Immunotherapy
2.25 AMA PRA Category 1 Credits
8:10 am - 8:50 am

Immunology 101
Stephen P. Shoenberger, PhD – La Jolla Institute for Asthma and Immunology
8:50 am - 9:20 am

Inflammation and Tumor Development
Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
9:20 am - 9:50 am

Immune Changes Associated with Tumor Growth and Regression
Jack D. Bui, MD, PhD – University of California, San Diego
9:50 am - 10:20 am
Panel Discussion
10:20 am - 10:35 am

Break

Session II: Targeting the Tumor
2 AMA PRA Category 1 Credits
10:35 am - 11:05 am

Current State of Immune Checkpoint Inhibitors
Omid Hamid, MD – The Angeles Clinic and Research Institute
11:05 am - 11:35 am

Oncolytic Virus Therapy in Cancer Immunotherapy
Robert Hans Ingemar Andtbacka, MD, CM, FACS, FRCSC – University of Utah
11:35 am - 12:05 pm

Cell Therapy
Mark Faries, MD – The John Wayne Cancer Institute
12:05 pm - 12:35 pm
Panel Discussion and Case Studies
12:35 pm - 1:20 pm

Lunch

Session III: New Combination Strategies: When More is Better and Less May be More
2.25 AMA PRA Category 1 Credits
1:20 pm - 1:50 pm

Combination Therapy
Bartosz Chmielowski, MD, PhD – University of California, Los Angeles
1:50 pm - 2:20 pm

Radiation and Immune Therapy
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center
2:20 pm - 2:50 pm

Biomarkers: How to Select the Correct Patient for Which Therapy
Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
2:50 pm - 3:20 pm
Panel Discussion and Case Studies
3:20 pm - 3:30 pm
Closing Remarks

Program Organizers

• Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
• Omid Hamid, MD –
The Angeles Clinic and Research Institute

Register By August 5, 2014 for Discounted Early Registration

Members are eligible for discounted registration rates. To receive the discounted rates listed below, your membership dues must be current through 2014. To renew your dues or apply for membership, please click here: www.sitcancer.org/membership

Member Early Rates

Student/Allied Health
FREE
Clinician/Academic
$50.00
Government
$50.00
Industry
$280.00


Non-Member Early Rates

Student/Allied Health
FREE
Clinician/Academic $50.00
Government $75.00
Industry $350.00

Remember! After the completion of the program, attendees will have free online access to program slides.

CME Credits Available

The Clinical Immunology Society designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. For full accreditation information, visit: www.sitcancer.org/sitc-meetings/aci2014/ca/aci-ca-cme-information

Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org

© 2014 Society for Immunotherapy of Cancer

Join us on:

Twitter  LinkedIn  YouTube  Oncology Tube

You have received this message because you have had previous contact with the Society for Immunotherapy of Cancer. If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.

Please add info@sitcancer.org to your safe senders list.